Compare · CCXI vs ILLU

CCXI vs ILLU

Side-by-side comparison of Churchill Capital Corp XI (CCXI) and Illumination Acquisition Corp I (ILLU): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both CCXI and ILLU operate in Blank Checks (Finance), so they compete in similar markets.
  • ILLU carries a market cap of $103.0M.
  • CCXI has hit the wire 40 times in the past 4 weeks while ILLU has been quiet.
  • CCXI has more recent analyst coverage (8 ratings vs 0 for ILLU).
MetricCCXIILLU
Company
Churchill Capital Corp XI
Illumination Acquisition Corp I
Price
-
$9.97-0.10%
Market cap
-
$103.0M
1M return
-
-0.10%
1Y return
-
+1.01%
Industry
Blank Checks
Blank Checks
Exchange
NASDAQ
NASDAQ
IPO
2026
2026
News (4w)
40
0
Recent ratings
8
0
CCXI

Churchill Capital Corp XI

ChemoCentryx, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of new medications for inflammatory disorders, autoimmune diseases, and cancer in the United States. It develops Avacopan, an orally administered selective complement 5a receptor inhibitor for the treatment of anti-neutrophil cytoplasmic autoantibody-associated vasculitis; and completed Phase II clinical trial for the treatment of patients with severe hidradenitis suppurativa, as well as patients with complement 3 glomerulopathy. The company is also developing CCX559, an orally-administered inhibitor for programmed death protein 1/programmed death-ligand 1 for the treatment of various cancers; and CCX507, an orally-administered inhibitor of the chemokine receptor CC9, which has completed Phase I clinical trial or the treatment of inflammatory bowel disease. In addition, it develops CCX587 for the treatment of TH17 driven diseases. ChemoCentryx, Inc. was incorporated in 1996 and is headquartered in Mountain View, California.